Sponsor: 
Sanofi-Aventis Australia
Administration route: 
Subcutaneous injection
Vaccine group: 
Japanese encephalitis vaccines

Registered for use in people aged ≥9 months.

Live attenuated Japanese encephalitis vaccine

Lyophilised powder in a monodose vial with separate diluent.

Each 0.5 mL reconstituted dose contains:

  • 4.0–5.8 log plaque-forming units of live attenuated recombinant Japanese encephalitis virus
  • mannitol
  • lactose
  • glutamic acid
  • potassium hydroxide
  • histidine
  • human serum albumin

No adjuvants or antibiotics are added.

For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018